Based on the Aprea Therapeutics stock forecast from 4 analysts, the average analyst Aprea stock price target is USD 2.50 over the next 12 months. Average analyst rating of Aprea Therapeutics Inc is Buy. Stock Target Advisor’s own stock analysis of Aprea Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Aprea Therapeutics stock price was USD 0.79. Aprea Therapeutics stock price has changed by -0.06% over the past week, -0.30% over the past month and -81.64% over the last year.
About Aprea Therapeutics Inc. (APRE:NSD):
Aprea Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company’s products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
What we like:
Superior risk adjusted returns:
Aprea stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value:
Aprea stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow:
Aprea Therapeutics Inc. had positive total free cash flow in the most recent four quarters.
What we don’t like:
Low market capitalization:
Aprea stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The total returns for Aprea Therapeutics stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Aprea Therapeutics Inc. had negative total cash flow in the most recent four quarters.
Low Earnings Growth:
Aprea Therapeutics stock has shown below median earnings growth in the previous 5 years compared to its sector